Skip to main content

Optogenetics

How Optogenetics Can Put the Brakes on Epilepsy Seizures


In what could one day become a new treatment for epilepsy, researchers at UC San Francisco, UC Santa Cruz and UC Berkeley have used pulses of light to prevent seizure-like activity in neurons in brain tissue taken from epilepsy patients as part of their treatment.

Eventually, they hope the technique will replace surgery to remove the brain tissue where seizures originate, providing a less invasive option for patients whose symptoms cannot be controlled with medication.

The team used a method known as optogenetics, which employs a harmless virus to deliver light-sensitive genes from microorganisms to a particular set of neurons in the brain. Those neurons can then be switched on or off with pulses of light.

When the brain is acting normally, neurons send signals at different times and frequencies in a predictable, low-level chatter. But during a seizure, the chatter synchronizes into loud bursts of electrical activity that overwhelm the brain’s casual conversation.

The team used the light pulses to prevent the bursts by switching off neurons that contained light-sensitive proteins.

It is the first demonstration that optogenetics can be used to control seizure-like activity in living human brain tissue, and it opens the door to new treatments for other neurological diseases and conditions.

“This represents a giant step toward a powerful new way of treating epilepsy and likely other conditions,” said Tomasz Nowakowski, PhD, an assistant professor of neurological surgery and a co-senior author of the study, which appears Nov. 15 in Nature Neuroscience.


Subduing epilepsy’s spikes

To keep the surgically removed tissue alive long enough to complete the study, which took several weeks, the researchers created an environment that mimics conditions inside the skull.

John Andrews, MD, a resident in neurosurgery, placed the tissue on a nutrient medium that resembles the cerebrospinal fluid that bathes the brain.

David Schaffer, PhD, a biomolecular engineer at UC Berkeley found the best virus to deliver the genes, so they would work in the specific neurons the team was targeting.

Andrews then placed the tissue on a bed of electrodes small enough to detect the electrical discharges of neurons communicating with each other.
Remote-control experimentation

First, the team needed to find a way to run their experiments without disturbing the tissue. The tiny electrodes were only 17 microns apart – less than half the width of a human hair – and the smallest movement of the brain slices could skew their results.

Mircea Teodorescu, PhD, an associate professor of electrical and computer engineering at UCSC and co-senior author of the study, designed a remote-control system to record the neurons’ electrical activity and deliver light pulses to the tissue.

Teodorescu’s lab wrote software that enabled the scientists to control the apparatus, so the group could direct experiments from Santa Cruz on the tissue in Nowakowski’s San Francisco lab.

That way, no one needed to be in the room where the tissue was being kept.

“This was a very unique collaboration to solve an incredibly complex research problem,” Teodorescu said. “The fact that we actually accomplished this feat shows how much farther we can reach when we bring the strengths of our institutions together.”
New insight into seizures

The technology allowed the team to see that they could stop the seizure-like activity by stimulating a surprisingly small number of neurons as well as determine the lowest intensity of light needed to change the electrical activity.

They were also able to observe how neurons interact while inhibiting a seizure.

These insights provide a deeper understanding of how the approach might be used to tightly regulate brain activity that leads to seizures and could spare patients the invasiveness and side effects of having brain tissue removed, said Edward Chang, MD, the chair of Neurological Surgery at UCSF.

“This kind of approach could really improve care for people with epilepsy,” said Chang, who, along with Nowakowski, is a member of the UCSF Weill Institute for Neurosciences. “We’ll be able to give people much more subtle, effective control over their seizures while saving them from such an invasive surgery.”

neural modulation, light-sensitive proteins, channelrhodopsin, halorhodopsin, optogenetic tools, neuronal circuits, brain mapping, optogenetic stimulation, optical fibers, genetically encoded actuators, neural network dynamics, synaptic plasticity, photocontrol, optogenetic therapy, microbial opsins, optogenetic gene delivery, behavioral neuroscience, functional connectivity, optical neurobiology, neuroengineering,

#Optogenetics, #Neuroscience, #BrainResearch, #NeuralModulation, #LightActivated, #Channelrhodopsin, #BrainMapping, #OpticalNeurobiology, #SynapticPlasticity, #Neurotechnology, #NeuralCircuits, #BrainHealth, #Photocontrol, #GeneDelivery, #OptogeneticTools, #Neuroengineering, #BehavioralNeuroscience, #FunctionalConnectivity, #NeuroscienceResearch, #BrainScience

Comments

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...

Type of Inherited Blindness in Dogs

Genetic test could eradicate a type of inherited blindness in dogs A mountain rescue dog whose duties ended after her eyesight failed has helped scientists create a test that could eradicate the genetic eye condition in her breed for good. Shola the English shepherd has an inherited eye disease called progressive retinal atrophy (PRA) that causes the light-sensitive cells at the back of the eye to deteriorate, eventually leading to blindness. PRA affects more than 100 dog breeds, can be caused by a number of different genetic variants and has no treatment. For some types, symptoms do not appear until the dog is several years old , by which point they may have passed their genes on to puppies. Katherine Stanbury, the first author of the research from the University of Cambridge, said Shola was four years old when she began struggling with her vision in dim light. “She was sent to a veterinary ophthalmologist and they confirmed that she had PRA,” said Stanbury. “And then it turned out h...